Peptides
Mitochondria do far more than generate cellular energy. They coordinate metabolic signaling, regulate inflammation, and appear to play a central role in how we age. Two peptides, MOTS-c and SS-31, have attracted serious scientific attention for their ability…
Mitochondria do far more than generate cellular energy. They coordinate metabolic signaling, regulate inflammation, and appear to play a central role in how we age. Two peptides, MOTS-c and SS-31, have attracted serious scientific attention for their ability to interact with mitochondrial function through distinct and complementary mechanisms. Here is what the current evidence actually shows, and where it falls short.
MOTS-c and SS-31 are both associated with mitochondrial health, but their origins are fundamentally different, and that distinction matters.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is encoded directly within the mitochondrial genome, specifically within the 12S rRNA region of mitochondrial DNA. According to sources including Polaris Peptides and DN Lab Research, this makes it part of a growing class of mitochondrial-derived peptides that the body produces naturally. MOTS-c circulates in the blood, can translocate to the nucleus, and appears to function as a metabolic signaling molecule. Its levels decline with age, which is one reason researchers consider it relevant to longevity science.
SS-31, also known as elamipretide, is a different story. Unlike MOTS-c, SS-31 does not exist naturally in the body. It is a synthetic tetrapeptide designed specifically to target mitochondrial membranes. As noted by Dr. Kristi Sawicki and the Peptide Database, SS-31 has been investigated in formal clinical trials for conditions including heart failure, Barth syndrome, and Friedreich's ataxia. It is not FDA-approved for general use, but it has moved further through the clinical research pipeline than most compounds in this space.
The two peptides target mitochondrial health through entirely different pathways, which is part of what makes studying them side by side interesting.
MOTS-c primarily functions as a metabolic regulator. Research suggests it activates AMPK (AMP-activated protein kinase), a master energy sensor that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. It has also been shown in preclinical studies to improve insulin sensitivity and physical endurance. Some research indicates MOTS-c can enter the nucleus and influence gene expression in response to metabolic stress, giving it a broader regulatory role beyond the mitochondria itself.
SS-31 works at the inner mitochondrial membrane, where it binds to cardiolipin, a phospholipid critical for the structure and function of the electron transport chain. By stabilizing cardiolipin, SS-31 appears to protect the efficiency of ATP production, reduce electron leak, and limit the generation of reactive oxygen species. The Peptide Database describes this mechanism as particularly relevant to aging tissues, where cardiolipin composition and integrity tend to decline over time.
Because these pathways are distinct, some researchers view them as potentially complementary rather than interchangeable, though no clinical evidence currently exists to support combined use in humans.
This is where honesty matters most. The research on both peptides is promising, but it is predominantly preclinical.
MOTS-c has shown measurable effects in animal models, including improved glucose metabolism, extended lifespan in mice, and enhanced exercise performance. DN Lab Research notes that MOTS-c remains a researched peptide with promising preclinical results in metabolic health, aging, and exercise physiology. Human data, however, is limited. There are observational findings, such as higher MOTS-c levels in centenarians, which raise interesting questions without establishing causation. Controlled clinical trials in humans are sparse.
SS-31 has a more developed clinical record. It has been evaluated in multiple human trials, primarily in the context of heart failure and rare mitochondrial diseases. Some of those trials have reported signals of benefit, though results have been mixed and the compound has not cleared the bar for FDA approval. Peptriva's research commentary is direct on this point: SS-31 marketed as a grey-market longevity peptide extrapolates well past its approved indications. That is a fair warning about the gap between clinical research settings and the current supplement or compounding landscape.
Neither peptide has established human evidence sufficient to make definitive claims about longevity, anti-aging, or disease prevention. The science is genuinely interesting. It is not yet conclusive.
Because neither peptide is FDA-approved for general use, access currently falls into two categories: participation in formal research or grey-market sourcing through compounding pharmacies or research chemical suppliers.
MOTS-c is not available as a standard pharmaceutical. Those who encounter it outside a clinical trial are sourcing it from compounding pharmacies or research suppliers, where quality control, purity, and dosing accuracy vary considerably. Biolongevity Labs and Peptriva both note the absence of regulatory chain of custody in this channel.
SS-31 (elamipretide) is further along clinically and has been compounded for use in some longevity medicine contexts, but it remains unapproved for the indications most often discussed in wellness circles. The administration route for both peptides is typically subcutaneous injection, which introduces additional considerations around sterility and technique.
Neither should be self-administered or sourced casually. Loti Labs and other sources note that these compounds are most appropriately used within experimental or supervised clinical protocols.
The risk profile of both peptides in humans is not fully characterized, which is itself an important limitation.
MOTS-c's safety data in humans is minimal. Animal studies have not raised major red flags, but the absence of reported harm in preclinical models does not establish human safety. Dosing parameters, long-term effects, and interactions with existing medications or conditions remain poorly understood outside controlled research settings.
SS-31 has more human safety data from its clinical trials, and it has generally been described as well-tolerated at doses studied. However, those trials used pharmaceutical-grade preparations under clinical supervision. Grey-market SS-31 carries the additional risks of unknown purity, incorrect dosing, and contamination. As Peptriva notes, there is no comparable quality assurance outside the regulated clinical setting.
For both peptides, the honest summary is this: the theoretical rationale is credible, the preclinical data is interesting, and the human evidence is insufficient to draw firm conclusions about benefit or risk in healthy individuals seeking longevity support.
If you are curious about mitochondrial peptides, that curiosity is reasonable given where the science is heading. But certain groups have more immediate reason to involve a licensed provider before going further.
You should speak with a qualified clinician before exploring these compounds if you have an established cardiovascular condition, a metabolic disorder such as type 2 diabetes, any mitochondrial disease, or if you are taking medications that affect energy metabolism or inflammation. Pregnant or breastfeeding individuals should avoid these compounds entirely given the absence of safety data. Anyone considering sourcing either peptide outside a formal clinical trial should discuss the regulatory and safety realities with a provider who understands the landscape.
A longevity-focused clinician can help you assess whether the current evidence is relevant to your specific health picture, and whether there are better-supported interventions worth prioritizing first.
MOTS-c and SS-31 represent a genuinely new direction in how researchers think about aging at the cellular level. The mechanisms are biologically plausible and the preclinical findings are worth following. But the human evidence remains thin, neither compound is FDA-approved for general wellness use, and the grey-market access points carry real unknowns. Watch this space with appropriate interest, and let the evidence mature before drawing conclusions about what these peptides can or cannot do for human longevity.
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. MOTS-c and SS-31 are not FDA-approved for general use or anti-aging purposes. Individual results cannot be guaranteed. Always consult a licensed healthcare provider before making decisions about your health or considering any investigational compound.
1. UAE Peptides, "Mitochondrial Health Through Peptides: MOTS-c vs SS-31" — https://uaepeptides.com/mitochondrial-health-motsc-ss31/ 2. Dr. Kristi Sawicki, "MOTS-c and SS-31: Two Mitochondrial Peptides Everyone Is Talking About" — https://drkristisawicki.substack.com/p/mots-c-and-ss-31-two-mitochondrial 3. DN Lab Research, "MOTS-c vs SS-31: Natural vs Synthetic Mitochondrial Peptides for Cellular Energy and Aging" — https://dnlabresearch.com/mots-c-vs-ss-31-difference-natural-vs-synthetic-mitochondrial-peptides/ 4. Polaris Peptides, "SS-31 Peptide vs MOTS-c in Mitochondrial Aging" — https://polarispeptides.com/ss-31-vs-mots-c-mitochondrial-aging-research/ 5. Biolongevity Labs, "SS-31 and MOTS-c: Two Mitochondrial Peptides Explained" — https://biolongevitylabs.com/research/ss-31-and-mots-c-mitochondrial-peptides/ 6. Loti Labs, "SS-31 vs MOTS-c: Choosing the Right Mitochondrial Peptide for You" — https://lotilabs.com/resources/ss-31-vs-mots-c-comprehensive-research-comparison-of-mitochondrial-peptides/ 7. Peptide Database, "Best Peptides for Mitochondrial Health: SS-31, MOTS-c, NAD+" — https://peptide-db.com/guides/mitochondrial-peptides 8. Peptriva, "SS-31 vs MOTS-c: Two Mitochondrial Peptides, Two Different Stories" — https://www.peptriva.com/research/ss-31-vs-mots-c-comparison
Ready when you are
Read the library first. When you want to act, start with a conversation with a licensed provider, entirely by telehealth.